Royalty Pharma (RPRX) Financial Guidance Impresses at First Public Analyst Day - BofA Securities
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Buy rating and $51.00 price target on Royalty Pharma (NASDAQ: RPRX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
